Characterization of Cytotoxic T-Lymphocyte Epitopes and Immune Responses to SARS Coronavirus Spike DNA Vaccine Expressing the RGD-Integrin-Binding Motif

W.P. Poh,1 T. Narasaraju,2 N.A. Pereira,2 F. Zhong,2 M.C. Phoon,2 P.A. Macary,2 S.H. Wong,2 J. Lu,2 D.R. Koh,1 and Vincent T.K. Chow2*

1Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore
2Department of Microbiology, Infectious Diseases Program, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore, Singapore

Integrins are critical for initiating T-cell activation events. The integrin-binding motif Arg-Gly-Asp (RGD) was incorporated into the pcDNA 3.1 mammalian expression vector expressing the codon-optimized extracellular domain of SARS coronavirus (SARS-CoV) spike protein, and tested by immunizing C57BL/6 mice. Significant cell-mediated immune responses were characterized by cytotoxic T-lymphocyte 51Cr release assay and interferon-gamma secretion ELISPOT assay against RMA-S target cells presenting predicted MHC class I H2-Kb epitopes, including those spanning residues 884–891 and 1116–1123 within the S2 subunit of SARS-CoV spike protein. DNA vaccines incorporating the Spike-RGD/His motif or the Spike-His construct generated robust cell-mediated immune responses. Moreover, the Spike-His DNA vaccine construct generated a significant antibody response. Immunization with these DNA vaccine constructs elicited significant cellular and humoral immune responses. Additional T-cell epitopes within the SARS-CoV spike protein that may contribute to cell-mediated immunity in vivo were also identified.

J. Med. Virol. 81:1131–1139, 2009.

© 2009 Wiley-Liss, Inc.

KEY WORDS: cellular and humoral immune responses; CTL epitopes; DNA vaccine; RGD-integrin-binding motif; SARS coronavirus; spike glycoprotein

INTRODUCTION

The global outbreak of severe acute respiratory syndrome (SARS) in 2003 seriously threatened public health and socioeconomic stability worldwide. Caused by the SARS-associated coronavirus (SARS-CoV), SARS is a newly emerged infectious disease that may recur at any time in the future [Leong et al., 2005; Surjit et al., 2006; Chow and Leong, 2009]. In view of the potential threat of a reemerging epidemic, much effort has been focused on the development of prophylactic vaccines against the highly pathogenic SARS-CoV [Bisht et al., 2004; Buchholz et al., 2004; Yang et al., 2004; Chen et al., 2005b]. Hence, the development of effective and safe vaccines is an urgent priority to prepare for a future SARS epidemic [ter Meulen et al., 2006].

The spike (S) protein of SARS-CoV is a type 1 transmembrane glycoprotein [Leth-Larsen et al., 2007]. The S1 subunit is responsible for virus binding to the angiotensin-converting enzyme 2 (ACE2) receptor [Li et al., 2003a; Prabakaran et al., 2004]. A fragment located in the middle of the S1 subunit (amino acids 318–510) constitutes the receptor-binding domain for ACE2 [Dimitrov, 2003; Wong et al., 2004]. The S2 subunit (which contains a putative fusion peptide and two heptad repeats HR1 and HR2) is responsible for the fusion between the viral and target cell membranes. These features make the S protein a suitable candidate for vaccine development. However, the level of overall sequence similarity between the predicted amino acid

Grant sponsor: Biomedical Research Council; Grant sponsor: Singapore and Microbiology Vaccine Initiative; Grant sponsor: National University of Singapore (Research Grants).
*Correspondence to: Vincent T.K. Chow, Professor, Department of Microbiology, Infectious Diseases Program, Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, Kent Ridge, Singapore 117597, Singapore.
E-mail: micctk@nus.edu.sg
Accepted 3 March 2009
DOI 10.1002/jmv.21571
Published online in Wiley InterScience
(www.interscience.wiley.com)
sequence of SARS-CoV spike glycoprotein and the spike glycoproteins of other coronaviruses is relatively low (20–27% pair-wise amino acid identity), except for some conserved sequences in the S2 subunit.

DNA-based vaccines have been shown to induce significant immune responses against several viral agents, including human immunodeficiency virus [Wang et al., 1993], influenza virus [Fynan et al., 1993], rabies virus [Xiang et al., 1994], and hepatitis B and C viruses [Davis et al., 1993; Lagging et al., 1995]. Unlike conventional vaccines employing either killed virus or purified antigens, DNA vaccination efficiently elicits cellular immune responses including cytotoxic T-lymphocyte (CTL) responses in addition to humoral immunity. The property of DNA vaccine-mediated cellular immunity to provide protection renders DNA vaccination a particularly attractive approach to control viral diseases. In general, only live virus vaccines or virus-like particles are capable of inducing CTL responses.

Several potential strategies can be considered for vaccination against SARS-CoV, including whole killed virus vaccines, live attenuated SARS-CoV vaccines, viral vectors such as adenovirus or vaccinia virus expressing SARS-CoV genes [Kitabatake et al., 2007], recombinant SARS-CoV proteins, and DNA-based vaccines [See et al., 2005; Huang et al., 2006].

However, DNA vaccines are not without shortcomings. The mechanisms by which DNA vaccines generate immune responses are complex. For intramuscular delivery of DNA, the majority of plasmids are thought to transfected muscle cells, which are poorly or only partially effective at presenting antigen and priming naïve immune cells [Nagaraju, 2001]. Instead, these cells are believed to produce antigen, which then transfer the antigen in some form to professional antigen-presenting cells (APCs) via a mechanism of cross-presentation such that MHC class I-restricted antigen-presenting cells (APCs) via a mechanism of cross-presentation such that MHC class I-restricted cytolysic T-cell responses can be elicited. In addition, plasmid DNA appears not to be simply an inert vector for delivering the gene [Liu et al., 2006].

Many innovative approaches have been adopted to develop gene-based adjuvants to improve the immunogenicity of candidate DNA vaccines. Targeting moieties have been explored as a means of enhancing DNA vaccination, including various ligands such as antibody fragments, transferrin, insulin, folate, and sugars [Harbottle et al., 1998].

Integrins are a class of related heterodimeric transmembrane surface receptors involved in cell–cell adhesion, and in the promotion of interactions between cells and components of the extracellular matrix glycoproteins (e.g., fibronectin and vitronectin), while their intracellular domains interact with the cytoskeleton. Integrin receptors mediate adhesive events that are critical for specific and effective immune responses to foreign pathogens. Integrin-dependent interactions of lymphocytes and APCs to endothelium regulate the efficiency and specificity of trafficking into secondary lymphoid organs and peripheral tissues. Within these sites, integrins facilitate cell movement through interactions with the extracellular matrix, and promote and stabilize antigen-specific interactions between T-lymphocytes and APCs that are critical for initiating T-cell activation events [Pribila et al., 2004]. The integrin-binding activity of adhesion proteins can be reproduced by short synthetic peptides containing the Arg-Gly-Asp (RGD) motif. Such peptides promote cell adhesion when insolubilized onto a surface, but inhibit adhesion when presented to cells in solution [Ruoslahti, 1996].

This study examined if the incorporation of the RGD-integrin-binding motif into a pcDNA3.1 mammalian expression construct comprising the codon-optimized extracellular domain of the SARS-CoV spike resulted in enhanced efficiency of DNA vaccination for inducing immune responses against SARS.

MATERIALS AND METHODS

Screening for H2-Kb-Restricted Peptides Within the SARS-CoV Spike Glycoprotein

The amino acid sequence of the Tor2 strain of SARS-CoV (GenBank accession no. NP828851) was used in the peptide prediction. To identify the potential H2-Kb-restricted CD8+ T-cell epitopes, computer-based programs were accessed through the RANKPEP and SYFPEITHI Epitope Prediction websites (http://bio.dfci.harvard.edu/RANKPEP/ and http://www.syfpeithi.de/). Ten potentially H2-Kb-restricted epitopes from the SARS-CoV spike glycoprotein were selected. The Ova257–264 epitope of chicken ovalbumin is a well-characterized H2-Kb epitope which served as the positive control.

Peptides and Cell Lines

Lyophilized peptides were purchased from Peptron (Daejeon, Korea), and their purity was confirmed by mass spectrometry. All peptides were dissolved in dimethyl sulfoxide to a concentration of 20 µg/µl, and stored at −80°C.

TAP2-deficient RMA-S cells are derived from T-cell lymphomas related to the Rauscher murine leukemia virus-induced RBL-5 cell line (kindly provided by Mariapia Degli-Esposti, University of Western Australia). Cell lines were cultured using Iscove’s modified Dulbecco’s medium (IMDM) supplemented with 10% heat-inactivated fetal calf serum (FCS), penicillin (100 U/ml), streptomycin (100 µg/ml), and 2-mercaptoethanol (55 µM) in a humidified atmosphere containing 5% CO2.

MHC-Peptide Binding Assay

To determine whether synthetic peptides bind to H2-Kb molecules, peptide-induced H2-Kb upregulation on RMA-S cells was examined. To measure the relative amounts of H2-Kb-peptide complexes formed, 2 × 10⁶ cells in 100 µl of 0.25% BSA and RPMI were seeded into Nuncion Surface 96-well round-bottom plates (Nunc,
Roskilde, Denmark), and maintained overnight at room temperature. Each peptide in 100 μl of medium was then added to a final concentration of 100 μM and incubated for 1 hr. The cells were then transferred to 37°C for 2 hr to allow any remaining peptide-free MHC molecules to denature. The cells were then washed with FACS buffer, and cell surface expression of H2-Kb molecules was detected by flow cytometry using fluorescein isothiocyanate-labeled goat anti-mouse H2-Kb antibody, clone CTKb (BD Biosciences, Franklin Lakes, NJ). Samples were run on a FACScan flow cytometer, and the data were analyzed using CellQuest software (Becton Dickinson Immunocytometry Systems, Franklin Lakes, NJ). The binding activity of each peptide was calculated as a ratio of the mean fluorescence of RMA-S cells loaded with peptide to the mean fluorescence of RMA-S without peptide.

**Plasmid Construction**

The codon-optimized SARS spike gene cloned into pcDNA3.1 (Invitrogen, Carlsbad, CA) was a kind gift from Michael Farzan, Harvard University, and was designated pScod-Harv [Li et al., 2003a]. A HindIII cleavage site was created in the extracellular-transmembrane border of the spike gene with human CD5 signal peptide cloned in pScod-Harv using the QuikChange XL Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) and the following primer pair (5'-GAGAGGCGCTGGCCTAAGAAC-3' and 5'-CACCCCAATCAGGAGAGTGTCC-3'). The human IgG Fc fragment cDNA was generated by PCR amplification of spleen cDNA template (reverse-transcribed from spleen total RNA) annealing with a pair of primers containing HindIII sites (5'-CCC-AAGCTTAAAATACACATGCCACC-3' and 5'-CCC-AAGCTTTCATTACACATGCCACC-3').

The human IgG Fc fragment cDNA was generated by PCR amplification of spleen cDNA template (reverse-transcribed from spleen total RNA) annealing with a pair of primers containing HindIII sites (5'-GTCGACATCATAATTTCGTGAATGT-3' and 5'-GGGAGGCCTGAAGTGAT-3'). The Fc, 6×His tag DNA fragment with HindIII sites was generated by PCR amplification of spleen cDNA template (reverse-transcribed from spleen total RNA) annealing with a pair of primers containing HindIII sites (5'-GTACGAGCTACGCCCTCCCACTC-3' and 5'-ATCACCATTGAA-3').

Five different sets of RMA-S cells were maintained at 37°C overnight in IMDM and 0.25% BSA without FCS, and were pulsed with 20 μl of each respective peptide (S436, S497, S525, S884, and S1116) at room temperature. Each peptide in 100 μl of medium was then added to a final concentration of 100 μM and incubated for 1 hr. The cells were then transferred to 37°C for 2 hr to allow any remaining peptide-free MHC molecules to denature. The cells were then washed with FACS buffer, and cell surface expression of H2-Kb molecules was detected by flow cytometry using fluorescein isothiocyanate-labeled goat anti-mouse H2-Kb antibody, clone CTKb (BD Biosciences, Franklin Lakes, NJ). Samples were run on a FACScan flow cytometer, and the data were analyzed using CellQuest software (Becton Dickinson Immunocytometry Systems, Franklin Lakes, NJ). The binding activity of each peptide was calculated as a ratio of the mean fluorescence of RMA-S cells loaded with peptide to the mean fluorescence of RMA-S without peptide.

The 6×His tag DNA fragment with HindIII sites at both ends was generated by a pair of oligonucleotides (5'-CGCTCCACCAACCGAGAAGCTTATCGTGTTGCTG-3' and 5'-GGTGATGATGGGGAGTCGCCGCGGCCA-3'). The RGD-His tag DNA fragment with HindIII sites at both ends was generated by a pair of oligonucleotides (5'-AGCTTGGCAGCGCTCCCTCCCATCACCACACATGCAA-3' and 5'-AGCTTTCTATGGGTGTGATGCTGTTGGGCGCCGCGCCA-3'). The Fc, 6×His tag and RGD/His tag DNA fragments were inserted into the HindIII sites of the HindIII-restricted pScod-Harv plasmid to generate spike extracellular (EC) domain-Fc fusion protein (S-Fc), spike extracellular domain-His tag fusion protein (S-His), and spike extracellular domain-RGD/His tag (S-RGD/His), respectively.

To construct the CD5 signal peptide-Fc (CD5SP-Fc) fusion protein, the CD5 signal peptide (CD5SP) fragment tail was first amplified at the 3' terminus with the first 12 bp of Fc fragment (Fragment 1) from the pScod-Harv plasmid using primers 1 and 2 (5'-TGGCTTAGCAGCCAAGCCGAC-3' and 5'-TGGCTTAGCAGCCAAGCCGAC-3'). The Fc fragment tagged at 5' terminus was then amplified with the last 12 bp of CD5SP fragment (Fragment 2) from the pScod-Harv-S-Fc plasmid using primers 3 and 4 (5'-TCCGTCTAGGCC(5-CD5SP)AAACTCACATGCGCCACC-3' and 5'-CCAAAGC(3'HindIII/TCTATTACCCGGAGACCGAG-3'). The CD5SP-Fc fragment from the mixture of fragments 1 and 2 was used as the template, and amplified by PCR using primers 1 and 4. The CD5SP-Fc fragment was then inserted into the XbaI and HindIII sites of the pcDNA3.1 vector to generate the CD5-Fc fusion protein gene expression vector. The various constructs are depicted in Figure 1.

**Mice and Immunizations**

Four- to 6-week-old female C57BL/6 mice were purchased and kept under normal animal holding conditions. Animal experiments were performed according to approved guidelines of the Institutional Animal Care and Use Committee, National University of Singapore. For DNA immunization, plasmids were replicated in Escherichia coli TOP10 cells, and cultured in LB culture medium at 37°C for 24 hr. Plasmids were prepared, extracted, and purified using an endotoxin-free plasmid extraction kit (Qiagen, Hilden, Germany). The plasmids were then purified using an endotoxin-free plasmid extraction kit (Qiagen, Hilden, Germany). The ratios of optical density at 260 and 280 nm wavelength ranged from 1.8 to 2.0. The endotoxin content of purified plasmid DNA was below 20 U/ml. Four- to 6-week-old female C57BL/6 mice (n = 7 per DNA vaccine group) were anesthetized, and given intramuscular injections into separate sites on each side of the quadriceps muscle, with a total dose of 100 μg of plasmid DNA dissolved in 100 μl of sterile phosphate-buffered saline (PBS). This was followed by three booster vaccinations of the same dose at 3-week intervals.

**Splenocyte Restimulation In Vitro**

To assess the cellular immune responses following priming injections, C57BL/6 mice were immunized intramuscularly with SARS-CoV spike DNA vaccines (i.e., S-RGD/His, S-His, S-Fc). Mice splenocytes were harvested 3 weeks after the last of four DNA vaccine immunizations. In vitro restimulation of primed splenocytes was achieved by using RMA-S cells as stimulators. Five different sets of RMA-S cells were maintained at 26°C overnight in IMDM and 0.25% BSA without FCS, and were pulsed with 20 μl of each respective peptide (S436, S497, S525, S884, and S1116) at room temperature.

**Fig. 1. Codon-optimized SARS-CoV spike (Spike-Fc, Spike-His, Spike-RGD/His) and control plasmid (CD5-Fc) constructs cloned into the pcDNA3.1 vector.**

*J. Med. Virol. DOI 10.1002/jmv*
temperature for 1 hr. Peptide-pulsed RMA-S cells were then irradiated at 7800 Rads. The ratio of splenocytes (responder) to individual peptide-pulsed RMA-S cells (stimulator) was 100:1. The splenocytes were stimulated with RMA-S cells pulsed with equal concentrations of the five high-binding epitopes. Given that there were five peptides used for the restimulation, the combined ratio was therefore 20:1. Cells were cultured in 10 ml of IMDM with 10% FCS in each flask for 4 days, with a maximum cell number of $7 \times 10^6$ per flask. Viable lymphocytes were harvested by density separation using Lympholyte-M (Cedarlane, Burlington, Canada), and subjected to CTL and interferon-γ (IFN-γ) ELISPOT assays.

**Cytotoxic T-Lymphocyte Assay**

Splenocytes restimulated in vitro were tested for cytotoxicity in a standard 4 hr $^{51}$Cr release assay. Target RMA-S cells were maintained overnight at room temperature, and pulsed with 20 μM of peptide at room temperature for 1 hr. The target cells were then labeled with $^{51}$Cr (100 μCi or 3.7 MBq per 10^6 cells) at 37°C for 1 hr. $^{51}$Cr-labeled target cells were washed thrice and 4 x $10^5$ cells were seeded into each well. These were then mixed with graded doses of effectors in Nunclon Surface 96-well plates, with effector-to-target ratios adjusted from 100:1 to 11:1. After incubation at 37°C for 4 hr, 40 μl of supernatant was transferred to a Lumac plate, and radioactivity was quantified using a TopCount gamma counter (Beckman Coulter, Fullerton, CA). Each assay was performed in triplicate, and the percentage of specific lysis was calculated by the formula: (experimental release – spontaneous release)/(maximum release – spontaneous release). Experimental release represented mean counts per minute released by target cells in the presence of effector cells. Maximum release represented the radioactivity released after lysis of target cells with 1% Triton X-100. Spontaneous release represented the radioactivity counted in the medium derived from target cells alone.

**IFN-γ ELISPOT Assay**

This assay was performed using the ELISPOT mouse set (BD Biosciences) according to the manufacturer's protocol. The 96-well polyvinylidene difluoride-backed plate was precoated with 5 μg/ml of rat anti-mouse IFN-γ monoclonal antibody in PBS overnight at 4°C. Plates were then washed thrice with PBS containing 0.25% Tween-20, and blocked with IMDM with 10% FCS, antibiotics, and 55 μM of 2-mercaptoethanol at 37°C for 2 hr. To obtain two data points, splenocytes were pooled from two groups of four and three mice. Splenocytes restimulated in vitro as effector cells (1 x $10^6$ per well, replicated thrice) and irradiated peptide-pulsed RMA-S cells (4 x $10^5$ per well, replicated thrice) were seeded in 200 μl of IMDM with 10% FCS at 37°C for 16 hr. Wells were extensively washed with PBS containing 0.05% Tween-20, and subsequently incubated with 2 μg/ml of biotinylated anti-mouse IFN-γ detection antibody at room temperature for 1 hr. After washing, wells were incubated with 5 μg/ml of streptavidin–horseradish peroxidase (HRP) antibody at room temperature for 1 hr. Wells were washed again, final substrate was added, and color development was monitored and stopped by washing with water. After drying overnight at room temperature, spots were counted using an ELISPOT Bioreader (Bio-Sys, Karben, Germany). The procedure was repeated with restimulated splenocytes (5 x $10^4$ per well, replicated six times) and irradiated peptide-pulsed RMA-S cells (5 x $10^4$ per well, replicated six times).

**Enzyme-Linked Immunosorbent Assay (ELISA)**

Sera from immunized mice of different groups were collected before and after the complete course of DNA vaccination, and the SARS-CoV antibody titers were measured by ELISA. Plates were coated with 6×His-tagged spike protein S1-1190 (at 10 μg/ml and 100 μl per well) of SARS-CoV Beijing02 strain (Immune Technology, Yonkers, NY), and incubated overnight at 4°C. Antigen was then decanted from wells, the plates were blocked with 100 μl of blocking solution (5% BSA, 1× PBS, 0.05% Tween-20) per well, and incubated at room temperature for 30 min. The plates were then washed thrice with 1× PBS with 0.05% Tween-20. Primary antibody (100 μl of mouse serum diluted 1:500 in 1× PBS) was added to each well. The plates were incubated in the dark at room temperature for 1.5 hr, and then washed thrice. Secondary anti-mouse antibody tagged with HRP (100 μl per well) was added, incubated at room temperature for 1.5 hr, and the plates washed thrice. O-phenylene diamine dihydrochloride substrate was added (100 μl per well), and incubated in the dark for 15 min. The reaction was stopped by adding 50 μl of 3 M sulfuric acid, and the absorbance was read at 490 nm.

**Statistical Analyses**

All data were expressed as means ± standard deviations for each group of immunized mice. The SPSS 13.0 software for Windows was used for statistical analyses, and a value of $P < 0.05$ was considered to be statistically significant.

**RESULTS**

**Identification of H2-Kb-Restricted Peptides Within the SARS-CoV Spike Glycoprotein by MHC-Peptide Binding Assay**

Based on computer software predictions by RANK-PEP and SYFPEITHI, 10 candidate octameric peptides (Table 1) with the highest estimated half-time dissociation from H2-Kb were selected and synthesized. To evaluate the binding affinities of these peptides to H2-Kb molecules, RMA-S cell-MHC-peptide binding tests were performed. This assay measures the increase in H2-Kb molecules induced on RMA-S cells following
exposure to exogenous H2-Kb-restricted peptides, with high-affinity peptides inducing H2-Kb upregulation more strongly than low affinity peptides.

Of the 10 candidate peptides, S497, S525, S884, and S1116 were found to be high-affinity epitopes, with mean fluorescence increase (MFI) of 6.58, 6.60, 4.81, and 1.89, respectively. Although S436 was previously identified as the dominant H2-Kb epitope [Zhi et al., 2005], we detected an MFI of only 1.23. The positive control Ova257 peptide bound H2-Kb strongly with an MFI of 3.68, whereas no or negligible binding was associated with the negative controls, that is, non-peptide bound (MFI = 1), H2-Kd-restricted hemagglutinin HA204 epitope (MFI = 1.14), I-Ab and I-Ad mouse MHC class II-restricted chicken ovalbumin Ova323 epitope (MFI = 1.03).

| Epitope            | Mean fluorescence increase | RANKPEP score | SYFPEITHI score |
|--------------------|---------------------------|---------------|-----------------|
| RMA-S control (no peptide loaded) | 1                         | NA            | NA              |
| HA204–212          | 1.14                      | NA            | 1–2             |
| Ova233–339         | 1.03                      | NA            | 1–6             |
| Ova257–264         | 3.68                      | 101           | 25              |
| S436–443*          | 1.23                      | 100           | 29              |
| S884–891*          | 4.81                      | 94            | 24              |
| S525–532*          | 6.60                      | 89            | 21              |
| S1116–1123*        | 1.89                      | 85            | 21              |
| S987–994           | 1.26                      | 85            | 17              |
| S175–182           | 1.63                      | 81            | 21              |
| S833–840           | 1.73                      | 80            | 22              |
| S760–767           | 1.71                      | 79            | 17              |
| S497–504*          | 6.58                      | 79            | 21              |
| S348–355           | 1.09                      | 78            | 22              |

For the MHC-peptide binding assay, the mean fluorescence increase (MFI) was calculated as the ratio of the fluorescence of peptide-loaded RMA-S cells to the fluorescence of unloaded RMA-S cells. MFI data are expressed as the means from two independent experiments conducted in duplicate for each peptide investigated. The epitope-binding constants were predicted from the RANKPEP and SYFPEITHI programs. Epitopes with asterisks were selected for further characterization. NA, not applicable.

**Cytotoxic T-Lymphocytes Are Activated Following SARS-CoV DNA Immunization**

A standard $^{51}$Cr release assay was performed to characterize the cytotoxicity of the restimulated splenocytes. RMA-S cells pulsed with each of the five specific high-binding epitopes (S436, S497, S525, S884, and S1116) were used as targets. Assays were performed in triplicate with an effector-to-target ratio from 100:1 to 11:1. RMA-S cells pulsed with an irrelevant epitope (Ova257–264) as well as non-epitope-presenting RMA-S cells acted as negative controls, and showed no cytotoxicity. Restimulated splenocytes of control mice immunized with PBS (Fig. 2A) as well as vector alone (Fig. 2B) also did not display any cytotoxicity. The cytotoxicity of restimulated splenocytes of mice immunized with S-His (Fig. 2C) and S-RGD/His (Fig. 2D) was similar, with the highest cytotoxicity levels observed against S1116-pulsed RMA-S cells.

**IFN-γ ELISPOT Assay Reveals T-Cell Epitopes of the SARS-CoV Spike Glycoprotein**

The IFN-γ-secreting capability of restimulated cells towards a stimulator was examined using a mouse IFN-γ ELISPOT assay. Splenocytes were cultured in the presence of peptide-pulsed and irradiated RMA-S targets, incubated, and spots counted with an ELISPOT reader.

An initial study involving splenocytes from mice immunized with S-Fc, S-His, S-RGD/His, vector only and CD5-Fc, as well as RMA-S stimulators presenting all 10 candidate epitopes (S175, S348, S436, S497, S525, S760, S833, S884, S987, and S1116) was carried out. A responder-to-stimulator ratio of 2.5:1 was used initially. S-RGD/His samples against the S1116, S833, S884, and S525 epitopes exhibited the greatest ratios over the non-pulsed cultures (Fig. 3). However, S-His samples cultured in RMA-S cells did not exhibit any significant difference between spike epitopes.

Based on MHC-peptide binding data and preliminary ELISPOT data, additional experiments were conducted on selected S-His and S-RGD/His samples for confirmation, and the responses towards the five strongly binding epitopes (S436, S497, S525, S884, and S1116) were evaluated. When the number of splenocytes tested and the number of stimulator cells were increased, both S-His and S-RGD/His responded vigorously towards RMA-S cells presenting S436, S525, and S1116 epitopes (Fig. 4).

**Immunization With SARS-CoV S-His DNA Vaccine Induces Significantly Higher Humoral Immune Responses Compared to S-RGD/His Vaccination**

The production of antigen-specific antibody induced by the SARS-CoV spike DNA vaccinations was assessed.
by coating spike protein (amino acids 1–1190) of SARS-CoV Beijin02 strain as the antigen. As expected, ELISA of sera from mice mock-immunized with (A) PBS, (B) pcDNA3.1 vector only, (C) S-His, and (D) S-RGD/His DNA vaccines revealed antibody levels close to the background. ELISA was performed on the sera of individual C57BL/6 mice (n = 7 per group) immunized with S-His or S-RGD/His DNA vaccines, and the mean values calculated. Sera from mice immunized with the S-His construct demonstrated approximately 3.5-fold higher levels of antibody to the spike glycoprotein than sera from mice immunized with the S-RGD/His DNA vaccine (Fig. 5). These data suggest that the serum antibody binding to the 6×His-tagged spike antigen was specific against the spike protein component since both the S-His and S-RGD/His constructs contained the 6×His tag. If the antibody responses were directed against the common His-tag component, one would detect similar antibody levels in both groups vaccinated with S-His and S-RGD/His constructs. Furthermore, Szewczuk et al. [1996] have documented that RGD-containing peptides show very weak stimulatory activity in humoral immunological response assays.

Fig. 2. Cytotoxic T-lymphocyte assay of stimulated splenocytes of mice immunized with (A) PBS, (B) pcDNA3.1 vector only, (C) S-His, and (D) S-RGD/His DNA vaccines. RMA-S cells were cultured overnight, and pulsed with 20 μM of each respective peptide for 1 hr. Target cells were pulsed with 35Cr at 37°C for 1 hr. Assays were performed in triplicate, and cytotoxicity was expressed as percentage lysis, that is, (sample release – spontaneous release)/maximum release – spontaneous release).

Data are expressed as the means of triplicate wells. No cytotoxicity was observed for restimulated splenocytes of mice mock-immunized with (A) PBS or (B) vector only. Asterisks denote statistical significance at P < 0.05 as analyzed by the Bonferroni method at effector-to-target (E:T) ratios of 11:1–100:1 for RMA-S targets pulsed with (C) S436 and S1116, and with (D) S884 and S1116.

Fig. 3. Preliminary mouse IFN-γ ELISPOT experiments to compare the efficacy of S-Fc, S-His, and S-RGD/His DNA vaccine constructs, and to assess putative T-cell epitopes of spike protein. Splenocytes (1 × 10⁶) were added to peptide-pulsed and irradiated RMA-S target cells (4 × 10³) at an effector-to-stimulator ratio of 2.5:1. ELISPOT assays were performed in triplicate, spots were counted with an ELISPOT reader, and mean values calculated. ELISPOT data are expressed as ratios of responders in the presence of peptide-pulsed over non-pulsed RMA-S stimulators. Asterisks denote statistical significance at P < 0.05 by the Dunnett two-sided t-test for ELISPOT cultures plus RMA-S stimulators pulsed with S525, S884, and S1116 within the S-RGD/His vaccinated group.

J. Med. Virol. DOI 10.1002/jmv
DISCUSSION

DNA vaccination shows great promise for eliciting protection against infectious diseases and other immune disorders, although the efficacy of DNA vaccines can vary widely due to differences in transfection efficiency of target tissues. DNA vaccines are mostly delivered into muscle tissue, which is poorly populated by immune cells such as dendritic cells, macrophages, or lymphocytes. Myocytes constitute the dominant cells that express antigens from DNA vaccines, but they are not APCs. The expressed antigens must be presented to APCs (such as dendritic cells), which migrate to draining lymph nodes to induce immune responses. Mechanisms that facilitate APC uptake of antigens are expected to enhance the efficacy of vaccines. Dendritic cells phagocytose apoptotic cells through the $\alpha_\text{v} \beta_5$ RGD-binding integrin, which promotes cross-presentation of antigens. RGD fusion to synthesized peptide antigens can enhance the immunogenicity of the peptide antigens, which may involve $\alpha_\text{v} \beta_5$-mediated antigen uptake.

Antigen-specific antibodies are induced by intranasal immunization with RGD-tagged antigens without adjuvants. In the present study, the RGD-integrin-binding motif was fused to the C-terminal end of the SARS-CoV spike antigen. The objective was to evaluate whether the short RGD tag could enhance immune responses against the spike antigen. Codon-optimized cDNA constructs increase protein antigen expression [Babcock et al., 2004], and we therefore used codon-optimized SARS-CoV spike cDNA to express RGD-tagged antigen [Yang et al., 2004; Zhong et al., 2006]. The spike antigen was expressed without the transmembrane and C-terminal domains, and with RGD fused together with a His tag for antigen purification and analysis. A SARS-CoV spike DNA vaccine without tags was shown to generate neutralizing antibody and protective immunity in mice [Yang et al., 2004]. In our experiments, the spike DNA vaccine was also potent in...
antibody induction. When the antigen was tagged with RGD, it exhibited a relative decrease in antibody induction, suggesting that either the RGD tag rendered spike protein less immunogenic or it polarized immune responses away from the humoral arm. The latter became clearer when cellular responses were assessed. With certain epitopes, S-RGD induced slightly higher CTL activation than S-His (Fig. 2C,D). IFN-γ secretion was also more effectively induced by S-RGD compared with S-His at an effector-to-stimulator ratio of 2.5:1 (Fig. 3). Therefore, the RGD tag appears to polarize the host from humoral to cellular responses, which is congruent with the initial hypothesis.

An unexpected but interesting observation following S-RGD DNA vaccine immunization was that the mice exhibited progressive fur loss with each booster dose leading to complete alopecia after the last boost. Alopecia was previously documented in human scalp xenografts upon laminin-10 inhibition using specific antibodies [Li et al., 2003b]. In the latter setting, laminins are major components of basement membranes to which epithelial cells attach, and interruption of these attachments may be expected to cause skin-related abnormalities [McGowan and Marinkovich, 2000]. However, it is yet unclear how immune responses against the RGD-tagged spike antigen cause skin-associated aberrations.

The receptor-binding domain is the major immunodominant portion and harbors potent neutralizing epitopes on the spike protein [Zhou et al., 2004; He et al., 2005; Wang et al., 2005]. The spike protein is necessary for the infectivity and pathogenicity of coronaviruses. Mutations in the spike gene correlate with altered pathogenesis, virulence, and tropism in other coronaviruses [Sanchez et al., 1999]. Zhi et al. [2005] identified the H-2b-restricted S436 and S525 epitopes, and concluded that the latter epitope was more dominant in C57BL/6 mice. The strength of these epitopes correlated with the binding affinity to H2-Kb as predicted by the SYFPEITHI algorithm. In contrast, we found that the S436 epitope was a relatively weak MHC binder with an MFI of only 1.23. Although S436 was ranked the highest MHC binder by the RANKPEP and SYFPEITHI predictions, the S497, S525, and S884 epitopes exhibited higher MFI values (6.58, 6.60, and 4.81, respectively) than S436. Two spike-specific CD8 T-cell epitopes were previously identified in C57BL/6 mice infected with mouse hepatitis virus (MHV), that is, dominant S510–518 and subdominant S598–605 [Castro and Perlman, 1995; Bergmann et al., 1996]. The dominant S510–518 epitope is located in a hypervariable region of the spike protein that appears to be readily deleted without loss of viability of MHV [Parker et al., 1989]. In comparison, the S436–443 dominant epitope resides in the minimal region of S1 required for interaction with its cellular receptor, ACE2 [Babcock et al., 2004; Tan et al., 2005]. In a study with SARS patient sera, Lu et al. [2004] discovered a fragment of spike protein (amino acids 441–700) to be the major immunodominant epitope.

This study demonstrated that prime-boost immunization of mice with SARS-CoV spike DNA vaccine constructs S-His and S-RGD/His induced significant antigen-specific cellular immune responses, IFN-γ stimulation, and CTL activation. Babcock et al. [2004] speculated that amino acids 1–510 of the spike glycoprotein represent a unique domain containing the receptor-binding site. Additionally, He et al. [2005] characterized the minimal receptor-binding domain to span residues 318–510, thus providing further supporting evidence that a vaccine targeting this region is highly promising. Based on the results of the present study, the S436 and S497 epitopes that reside within this region are highly immunogenic. CTL induction by both S-His and S-RGD/His DNA vaccines kill RMA-S cells which were pulsed with the S436, S497, S525, S884, and S1116 epitopes. Furthermore, these epitopes also stimulated IFN-γ secretion.

In addition to the S436 and S525 epitopes [Zhi et al., 2005], the S884 epitope was discovered to be another strong MHC binder that elicited cytotoxic T-cell responses. Even though the S1116 peptide was predicted by bioinformatics to be a weak MHC binder, it induced the strongest cytotoxic T-cell response (Fig. 2) as well as the highest IFN-γ production (Fig. 3) among all peptides tested. The S884 and S1116 epitopes are close to the carboxyl end of the spike protein where the S2 subunit resides. Wang et al. [2004] reported that a S1167 epitope (RLNEVAKNL) within the S2 subunit could induce peptide-specific CTLs in both HLA-A2.1/Kb transgenic mice and human peripheral blood mononuclear cells. Chen et al. [2005a] revealed that peripheral blood cells of recovered SARS patients with HLA*0201 recognize epitopes S978 and S1202 within the S2 subunit which mediates viral fusion with target cell membranes. Additionally, Tsao et al. [2006] identified S787 and S1042 epitopes to be HLA-A*0201-restricted. In view of our finding that the S884 and S1116 epitopes within S2 subunit were potent inducers of cytotoxic T-cell responses and IFN-γ production, the S2 domain also represents an important target for vaccine development, especially in cytotoxic T-cell stimulation. Hence, the S2 subunit is complementary to the S1 domain, which has been demonstrated to be crucial for the development of immunogenic vaccines against SARS-CoV.

ACKNOWLEDGMENTS

We are grateful to Dr. Y.H. Chan for statistical analyses, N.P. Ramachandran, and Kelly Lau for technical assistance.

REFERENCES

Babcock GJ, Eshashki DJ, Thomas WD, Ambrosino DM. 2004. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol 78:4552–4560.

Bergmann CC, Yao Q, Lin M, Stohman SA. 1996. The JHM strain of mouse hepatitis virus induces a spike protein-specific Db-restricted cytotoxic T cell response. J Gen Virol 77:315–325.

Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B. 2004. Severe acute respiratory syndrome
coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 101:6641–6646.

Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K. 2004. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 101:9804–9809.

Castro RF, Perlman S. 1995. CD8

Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Chen H, Hou J, Jiang X, Ma S, Meng M, Wang B, Zhang M, Zhang M, Tang Z, Zhang F, Tan T, Li N, Yu Y, Hu H, Yang R, He W, Wang X, Cao X. 2005a. Response of memory CD8+ T cells to severe acute respiratory syndrome (SARS) coronavirus in recovered SARS patients. J Virol 79:1827–1831.

Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang F, Wei Q, He T, Yu W, Yu J, Gao H, Tu X, Gettie A, Farzan M, Yuen KY, Ho DD. 2005b. Reombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus type 1 mediates neutralizing antibodies primarily targeting the receptor binding domain. J Virol 79:2678–2688.

Chow VT, Leong WF. 2009. Severe acute respiratory syndrome coronavirus induces differential host gene expression responses associated with pathogenesis. In: Yang D, editor, RNA viruses—Host gene responses to infections. Singapore: World Scientific. pp 295–320.

Davis HL, Michel ML, Quale AC, Mueller KL, Shimizu Y. 2004. Integrins and mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 101:6641–6646.

Diels HL, Michel ML, Whalen RG. 1993. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet 2:1847–1851.

Dimitrov DS. 2003. The secret life of ACE2 as a receptor for the SARS coronavirus spike glycoprotein. J. Med. Virol. 76:960–968.

Harbottle RP, Cooper RG, Hart SL, Ladhoff A, McKay T, Knight AM, Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson SW, Kwang J. 2004. Immunological characterization of the spike protein of the severe acute respiratory syndrome coronavirus. J Virol 78:1906–1910.

Huang X, Lu S. 2005. Identification of two neutralizing regions on the human SARS coronavirus spike protein. Virology 335:34–45.

J Virol 73:7607–7618.

J Med. Virol. DOI 10.1002/jmv

coronavirus spike protein. Virology 199:132–140.

McGowan KA, Marinkovich MP. 2000. Laminins and human disease. Microsc Res Tech 51:262–279.

Nagamura K. 2001. Immunological capabilities of skeletal muscle cells. Acta Physiol Scand 171:213–223.

Parker SE, Gallagher TM, Buchmeier MJ. 1989. Sequence analysis reveals extensive polymorphism and evidence of deletions within the E2 glycoprotein gene of several strains of murine hepatitis virus. Virology 173:664–673.

Prabakaran P, Xiao X, Dimitrov DS. 2004. A model of the ACE2 structure and function as a SARS-CoV receptor. Biochim Biophys Res Commun 314:235–241.

Pribila JT, Quale AC, Mueller KL, Shimizu Y. 2004. Integrins and T cell-mediated immunity. Annu Rev Immunol 22:157–180.

Ruoslahti E. 1996. RGD and other recognition sequences for integrins. J Biol Chem 271:1657–1647.

See RH, Roper RL, Brunham RC, Finlay BB. 2005. Rapid response research—SARS coronavirus vaccines and application of processes to other emerging infectious diseases. Curr Immuno Rev 1:185–200.

Subbarao K, Collins PC. 2004. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 101:9804–9809.

Tan YJ, Lim SG, Hong W. 2005. Characterization of viral proteins encoded by the SARS coronavirus genome. Antiviral Res 65:69–78.

Ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Denventer E, Preiser W, Doerr LH, Chow VT, de Kruif J, Peiris JS, Goudsmit J. 2006. Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants. PLoS Med 3:e237.

Tsao YP, Lin JY, Jan JT, Leng CH, Chu CC, Yang YC, Chen SL. 2006. HLA-A*0201 T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus nucleoplasid and spike proteins. Biochem Biophys Res Commun 344:63–71.

Wang B, Ugen KE, Srikanthan V, Agadjanyan MG, Dang K, Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB. 1993. Gene inoculation generates immune responses in vaccinated and infected mice. Cell 73:1049–1058.

Wang B, Chen H, Jiang X, Zhang M, Wan T, Li N, Zhou X, Wu Y, Yang F, Yu Y, Wang X, Yang R, Cao X. 2004. Identification of an HLA-A*0101-restricted CD8+ T-cell epitope Sep-1 of SARS-CoV spike protein. Blood 104:200–206.

Wang S, Choi TH, Sakahatsky PV, Huang S, Lawrence JM, Cao H, Huang X, Lu S. 2005. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol 79:1906–1910.

Wong SK, Li W, Moore MJ, Choe H, Farzan M. 2004. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 279:3179–3201.

Xiang ZQ, Spitalnik S, Tran M, Wunner WH, Cheng J, Ertl HC. 1994. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology 199:132–140.

Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ. 2004. An adenovirus vector induces SARS coronavirus neutralization and protective immunity in mice. Nature 428:561–564.

Zhu Y, Kohninger GP, Jordan H, Suchma K, Weiss SR, Shen H, Schmer G, Gao G, Boyer JL, Crystal RG, Wilson JM. 2005. Identification of murine CD8+ T cell responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90:4136–4160.

Zhou X, Zhang F, Wan T, Li N, Zhou X, Wu Y, Yang F, Yu Y, Wang X, Yang R, Cao X. 2004. Identification of an HLA-A*0101-restricted CD8+ T-cell epitope Sep-1 of SARS-CoV spike protein. Blood 104:200–206.

Zhou T, Wang H, Luo D, Rowe T, Wang Z, Hogan B, Qiu S, Bunzel BD, Huang G, Mishra V, Voss TG, Kimberly R, Luo M. 2004. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies. J Virol 78:7217–7226.